AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 141 min read$CAH

CAH: Guidance targets 13%-15% EPS growth in 2027, led by specialty and pharma investments

Cardinal Health (CAH) projects 13%-15% EPS growth by 2027, driven by specialty, pharma, and at-home solutions. Growth is supported by strategic relationships, diversified revenue, and proactive policy management, according to the company's guidance at Morgan Stanley's conference.

Original reporting
tradingview.com
Published Sep 14, 2026, 1:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 2:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CAH: Guidance targets 13%-15% EPS growth in 2027, led by specialty and pharma investments — source image
Source · tradingview.com
Decision brief

The 30-second read

$CAHBullishHigh
01

Why it matters

Guidance suggests stronger earnings trajectory, likely influencing stock valuation.

02

Market read

Guidance may affect healthcare distribution sector and related equities.

03

What to watch

Potential supply chain constraints and reimbursement policy changes could hinder growth.

Relevance 9/10Novelty 9/10Timing: guidance released Sep 14 2026

Background

Cardinal Health presented FY2027 guidance at Morgan Stanley conference.

Company-level read

Ticker impact

$CAHBullishHigh confidence
Context

Guidance projects 13%-15% EPS growth for fiscal 2027.

Expected impact

Potential upside as investors price in higher earnings growth.

Evidence & confidence

Guidance exceeds prior expectations, supporting a bullish outlook.

Market effects

Sector

Positive outlook may boost healthcare distribution sector.

Regional

U.S. healthcare stocks could see modest gains.

Global

Limited, primarily U.S. market focus.

Counterpoint

What could challenge this read

Skeptics may argue growth targets are ambitious amid margin pressures.

Key entities

  • company
    Cardinal Health, Inc.

    U.S. healthcare services provider.

Read at source← All news

Related articles

SEP 11
$CAHHighAI 8/10

CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?

Cardinal Health (CAH) shares rose 29.3% over four months, driven by strong earnings from specialty businesses. Q4 2026 revenue increased 6% to $63.7B, with operating earnings up 30% to $935M. The company expects 3-5% pharma revenue growth in 2027 but 8-11% segment profit growth. Specialty business grew 25% in 2026, and acquisitions like Solaris are boosting growth. CAH trades at a forward P/E of 18.41X, above its 5-year median but below the S&P 500's 19.83X.

theglobeandmail.com2 min
SEP 3
$CAHHighAI 8/10

Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”

Jim Cramer highlighted Cardinal Health (CAH) as a favorite, citing its specialty pharmaceuticals and healthcare services growth. Q4 revenue rose 6% to $63.7B but missed estimates, while adjusted EPS was $2.91. Fiscal 2027 guidance includes non-GAAP EPS of $12.40-$12.60 and adjusted free cash flow of $3.5B-$4B. Risks include execution, drug pricing, and customer concentration.

insidermonkey.com3 min